These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 8101225)

  • 1. Neurochemical and behavioral evidence that Ro 41-9067 is a selective presynaptic dopamine receptor agonist.
    Nisoli E; Tonello C; Imhof R; Scherschlicht R; da Prada M; Carruba MO
    J Pharmacol Exp Ther; 1993 Jul; 266(1):97-105. PubMed ID: 8101225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological profile of the dopamine partial agonist, (+/-)-PD 128483 and its enantiomers.
    Meltzer LT; Caprathe BW; Christoffersen CL; Corbin AE; Jaen JC; Ninteman FW; Pugsley TA; Serpa KA; Shih YH; Whetzel SZ
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1177-89. PubMed ID: 8103791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological characterization of PD 118717, a putative piperazinyl benzopyranone dopamine autoreceptor agonist.
    Pugsley TA; Christofferson CL; Corbin A; DeWald HA; Demattos S; Meltzer LT; Myers SL; Shih YH; Whetzel SZ; Wiley JN
    J Pharmacol Exp Ther; 1992 Dec; 263(3):1147-58. PubMed ID: 1361570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation.
    Hess EJ; Albers LJ; Le H; Creese I
    J Pharmacol Exp Ther; 1986 Sep; 238(3):846-54. PubMed ID: 3018223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects.
    Rugsley TA; Davis MD; Akunne HC; Cooke LW; Whetzel SZ; MacKenzie RG; Shih YH; van Leeuwen DH; DeMattos SB; Georgic LM
    J Pharmacol Exp Ther; 1995 Aug; 274(2):898-911. PubMed ID: 7636753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of buspirone on dopamine dependent behaviours in rats.
    Dhavalshankh AG; Jadhav SA; Gaikwad RV; Gaonkar RK; Thorat VM; Balsara JJ
    Indian J Physiol Pharmacol; 2007; 51(4):375-86. PubMed ID: 18476392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RDS-127 (2-di-n-propylamino-4,7-dimethoxyindane): central effects of a new dopamine receptor agonist.
    Arnerić SP; Long JP; Williams M; Goodale DB; Mott J; Lakoski JM; Gebhart GF
    J Pharmacol Exp Ther; 1983 Jan; 224(1):161-70. PubMed ID: 6401334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo comparisons of the effects of quinpirole and the putative presynaptic dopaminergic agonists B-HT 920 and SND 919 on striatal dopamine and acetylcholine release.
    Robertson GS; Tham CS; Wilson C; Jakubovic A; Fibiger HC
    J Pharmacol Exp Ther; 1993 Mar; 264(3):1344-51. PubMed ID: 8095550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical and functional identification of a novel dopamine receptor subtype in rat brown adipose tissue. Its role in modulating sympathetic stimulation-induced thermogenesis.
    Nisoli E; Tonello C; Memo M; Carruba MO
    J Pharmacol Exp Ther; 1992 Nov; 263(2):823-9. PubMed ID: 1359119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.
    Kikuchi T; Tottori K; Uwahodo Y; Hirose T; Miwa T; Oshiro Y; Morita S
    J Pharmacol Exp Ther; 1995 Jul; 274(1):329-36. PubMed ID: 7616416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roxindole: psychopharmacological profile of a dopamine D2 autoreceptor agonist.
    Bartoszyk GD; Harting J; Minck KO
    J Pharmacol Exp Ther; 1996 Jan; 276(1):41-8. PubMed ID: 8558454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
    Chipkin RE; Iorio LC; Coffin VL; McQuade RD; Berger JG; Barnett A
    J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behavioral responsitivity to dopamine receptor agonists after extensive striatal dopamine lesions during development.
    Neal-Beliveau BS; Joyce JN
    Dev Psychobiol; 1998 May; 32(4):313-26. PubMed ID: 9589220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Desensitization of rat striatal dopamine-stimulated adenylate cyclase after acute amphetamine administration.
    Barnett JV; Kuczenski R
    J Pharmacol Exp Ther; 1986 Jun; 237(3):820-5. PubMed ID: 2940359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative selectivity of 6,7-dihydroxy-2-dimethylaminotetralin, N-n-propyl-3-(3-hydroxyphenyl)piperidine, N-n-propylnorapomorphine and pergolide as agonists at striatal dopamine autoreceptors and postsynaptic dopamine receptors.
    Claustre Y; Fage D; Zivkovic B; Scatton B
    J Pharmacol Exp Ther; 1985 Feb; 232(2):519-25. PubMed ID: 2857197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
    Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
    J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between receptor occupancy and response at striatal dopamine autoreceptors.
    Meller E; Bohmaker K; Namba Y; Friedhoff AJ; Goldstein M
    Mol Pharmacol; 1987 Jun; 31(6):592-8. PubMed ID: 2885734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cocaine acts on accumbens monoamines and locomotor behavior via a 5-HT2A/2C receptor mechanism as shown by ketanserin: 24-h follow-up studies.
    Broderick PA; Olabisi OA; Rahni DN; Zhou Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 May; 28(3):547-57. PubMed ID: 15093963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postsynaptic 5-HT(1A) receptors mediate an increase in locomotor activity in the monoamine-depleted rat.
    Mignon L; Wolf WA
    Psychopharmacology (Berl); 2002 Aug; 163(1):85-94. PubMed ID: 12185404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical studies on quinelorane, a potent and highly selective D2-dopaminergic agonist.
    Foreman MM; Fuller RW; Hynes MD; Gidda JS; Nichols CL; Schaus JM; Kornfeld EC; Clemens JA
    J Pharmacol Exp Ther; 1989 Jul; 250(1):227-35. PubMed ID: 2526214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.